Learn how incorporating real-world data at study design can improve feasibility, reduce amendments, and align eligibility ...

Understand how combining proprietary and real-world datasets with tokenization enables accurate protocol matching while ...

Roughly 70 to 80% of ovarian cancer cases are diagnosed at an advanced stage,1 where treatment options are limited and ...

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has directed Boehringer ...

The Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO) has sought major ...

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

In an interview with Targeted Oncology at the 2025 North American Neuroendocrine Tumor Society (NANETS) Symposium, Michael ...

Research and development expenses for the third quarter of 2025 were $52.4 million versus $37.1 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...

IMM-529 IND: currently under review, FDA request for Information - minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data de ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...

The GOALPOST Trial builds on the findings of CHAP and Sinkey’s preliminary clinical trial, called the ACHIEVE Trial, which is ...

Discover three strategies for MedTech companies to design streamlined, effective trials and how quality data powers smarter ...